



IAP7 Rec'd PCT/PTO 33 APR 2006

PTO/SB/21 (09-04)

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

5+21
refs

Application Number

10/552,177

Filing Date

October 5, 2005

First Named Inventor

Joseph M. Ahearn

Art Unit

1641

Examiner Name

Attorney Docket Number

021182-000410US

ENCLOSURES (Check all that apply)

- | | | |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance Communication to TC |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment/Reply | <input type="checkbox"/> Petition | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Terminal Disclaimer | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Request for Refund | Return Postcard |
| <input checked="" type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| | <input type="checkbox"/> Landscape Table on CD | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430. | |
| <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application | | |
| <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Townsend and Townsend and Crew LLP

Signature

Printed name

Kenneth A. Weber

Date

3/30/06

Reg. No.

31,677

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature

Typed or printed name

Julie Taylor Clough

Date

3/30/06

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On March 30, 2006

TOWNSEND and TOWNSEND and CREW LLP

By: Julie Taylor Chouh

PATENT
Attorney Docket No.: 021182-000410US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Joseph M. Ahearn

Application No.: 10/552,177

Filed: October 5, 2005

For: IDENTIFICATION AND
MONITORING OF SYSTEMATIC
LUPUS ERYTHEMATOSUS

Examiner: Unassigned

Art Unit: 1641

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the non-patent references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kenneth A. Weber
Reg. No. 31,677

Dated: 3-28-02

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KAW:jtc
Enclosures
60735202 v1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/552,177	
			Filing Date	October 5, 2005	
			First Named Inventor	Ahearn, Joseph M.	
			Art Unit	1641	
			Examiner Name	Unassigned	
Sheet	1	of	3	Attorney Docket Number	021182-000410US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AA	US-2005/0037441 A1	02-17-2005	Ahearn et al.	
	AB	US-2005/0042602 A1	02-24-2005	Ahearn et al.	
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AS	WO	03/022223 A2		20-03-2003	Univ. of Pittsburg		<input type="checkbox"/>
	AT	WO	94/10571 A1		05-11-1994	T Cell Sciences Inc.		<input type="checkbox"/>
	AU							<input type="checkbox"/>
	AV							<input type="checkbox"/>
	AW							<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60735202 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/552,,177
				Filing Date	October 5, 2005
				First Named Inventor	Ahearn, Joseph M.
				Art Unit	1641
Examiner Name	Unassigned				
Attorney Docket Number	021182-000410US				
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AX	ALEXANDER, Elaine, et al., " <u>Serum complement activation in central nervous system disease in sjogren's syndrome</u> ," The American Journal of Medicine, October 1988, Vol. 85, No. 4, abstract only.	<input type="checkbox"/>	
	AY	ATKINSON, J.P., et al., " <u>Origin of the Fourth Component of Complement Related Chido and Rodgers Blood Group Antigens</u> ," 1988; Complement; Vol. 5; pp. 65-76	<input type="checkbox"/>	
	AZ	BOMBARDIER, Claire, et al., " <u>Derivation of the SLEDAI A Disease Activity Index for Lupus Patients</u> ," Arthritis Rheum, June 1992, Vol. 35; No. 6; pp. 630-640.	<input type="checkbox"/>	
	AAA	CHUDWIN, D., et al., " <u>Activation of the Alternative Complement Pathway by Red Blood Cells from Patients with Sickle Cell Disease</u> ," Clinical Immunology and Immunopathology, May 1994, Vol. 71, No. 2, pp. 199-202.	<input type="checkbox"/>	
	ABB	CORVETTA, Angelo, et al.; " <u>Low Number of Complement C3b/C4b Receptors (CR1) on Erythrocytes from Patients with Essential Mixed Cryoglobulinemia, Systemic Lupus Erythematosus and Rheumatoid Arthritis: Relationship with Disease Activity, Anticardiolipin Antibodies, Complement Activation and Therapy</u> ," 1981, J. Rheumatol., Vol. 18, pp. 1021-1025.	<input type="checkbox"/>	
	ACC	COSIO, F.G., et al., " <u>The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients</u> ," Transplantation, October 27, 1996, Vol. 62, No. 8, abstract only.	<input type="checkbox"/>	
	ADD	FREYSDOTTIR, Jona, et al.; " <u>A flow cytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes</u> ," 1991, Journal of Immunological Methods, Vol. 142, pp. 45-52.	<input type="checkbox"/>	
	AEE	JOUVIN, Marie-Helene et al.; " <u>Decreased Expression of C3b Receptor (CR1) on Erythrocytes of Patients with Systemic Lupus erythematosus Contrasts with Its Normal Expression in Other Systemic Diseases and Does Not Correlate with the Occurrence or Severity of SLE Nephritis</u> ," Complement; 1986, Vol. 3, pp. 88-96.	<input type="checkbox"/>	
	AFF	LACH-TRIFILIEFF, Estelle, et al., " <u>Complement Receptor 1 (CD35) on Human Reticulocytes: Normal Express in Systemic Lupus Erythematosus and HIV-Infected Patients</u> ," The Journal of Immunology, Vol. 162, No. 12, June 1999, pp. 7549-7554.	<input type="checkbox"/>	
	AGG	LAMPRECHT, P., et al., " <u>Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis</u> ," Annals of the Rheumatic Diseases, April 2001, Vol. 60, pp. 385-390.	<input type="checkbox"/>	
	AHH	LIANG, Matthew H., et al., " <u>Reliability and Validity of Six Systems for the Clinical Assessment of Disease Activity in Systemic Lupus Erythematosus</u> ," Arthritis Rheum, September 1989, Vol. 32; No. 9; pp. 1107-18.	<input type="checkbox"/>	
Examiner Signature				Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/552,,177
				Filing Date	October 5, 2005
				First Named Inventor	Ahearn, Joseph M.
				Art Unit	1641
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	021182-000410US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	All	MANZI, Susan, et al.; " <u>Measurement of Erythrocyte C4d and Complement Receptor 1 in Systemic Lupus Erythematosus</u> ;" November 2004, Arthritis & Rheumatism, Vol. 50, No. 11, pp. 3596-3604.	<input type="checkbox"/>	
	AJJ	ACCN. No. 85046338 MEDLINE. MCCARTHY, T., et al., " <u>Intrauterine devices and pelvic inflammatory disease</u> ;" Australian and New Zealand Journal of Obstetrics and Gynecology, May 1984, Vol. 24, No. 2, pp. 106-110, Abstract.	<input type="checkbox"/>	
	AKK	MCGEER, P.L. et al.; " <u>Reactions of the Immune System in Chronic Degenerative Neurological Diseases</u> ;" The Canadian Journal of Neurological Sciences; 1991, Vol. 18; pp. 376-379.	<input type="checkbox"/>	
	ALL	ACCN. No. 90367342 MEDLINE. MELICONI, R., et al., " <u>Complement activation products in idiopathic pulmonary fibrosis: relevance of fragment Ba to disease severity</u> ;" Clinical Immunology and Immunopathology, October 1990, Vol. 57, No. 1, pp. 64-73, Abstract.	<input type="checkbox"/>	
	AMM	ROSS, Gordon D. et al.; " <u>Disease-Associated Loss of Erythrocyte Complement Receptors (CR1, C3b Receptors) in Patients with Systemic Lupus Erythematosus and other Diseases Involving Auto antibodies and/or Complement Activation</u> ;" 1985, Journal of Immunology, Vol. 135, No. 3, pp. 2005-2014.	<input type="checkbox"/>	
	ANN	SIROIS, M., et al., " <u>An Enzyme-linked Immunosorbent Assay for the Detection of Complement Components on Red Blood Cells</u> ;" Am. Journ. Clin. Path., July 1984, Vol. 82, No. 1, pp. 67-73.	<input type="checkbox"/>	
	AOO	TAUSK, Francisco, et al., " <u>The Expression of C3b Receptors in the Differentiation of Discoid Lupus Erythematosus and Systemic Lupus Erythematosus</u> ;" Arthritis and Rheumatism, June 1990, Vol. 33, No. 6, pp. 888-892.	<input type="checkbox"/>	
	APP	TILLEY, C.A., et al., " <u>Localisation of Chido and Rodgers Determinants to the C4d Fragment of Human C4</u> ;" Nature; December 14, 1978; Vol. 276; pp. 713-715.	<input type="checkbox"/>	
	AQQ	TSUBOI, Y. et al.; " <u>Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis</u> ;" Neurosurgery and Psychiatry 1994, Vol. 57, pp. 859-861.	<input type="checkbox"/>	
	ARR	YAMADA, T., et al. " <u>Complement-activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d</u> ;" Neuroscience Letters, 1990, Vol. 112, pp. 161-166.	<input type="checkbox"/>	
	ASS		<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.